Ironwood Q4 revenue $47.7M, GAAP net loss $2.3M; FY adj EBITDA $138M, guides FY26 >$300M

IRONWOOD PHARMACEUTICALS INC

2025-FY EPS reported $0.15 vs consensus $0.01 ▲ beat (+1370.6%)

Full-year 2025 total revenue $296M, GAAP net income $24M ($0.15 diluted EPS), adjusted EBITDA $138M.
Q4 2025 total revenue $47.7M (down 47% YoY); GAAP net loss $2.3M vs net income $2.3M in Q4 2024.
LINZESS EUTRx demand grew 11% YoY in FY2025; over 5.7M unique patients treated since launch.
Provides FY2026 guidance: LINZESS U.S. net sales $1.125-1.175B, total revenue $450-475M, adj EBITDA >$300M.
Apraglutide confirmatory Phase 3 trial (STARS-2) design finalized; site initiations expected Q2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.